Citius Pharmaceuticals, Inc. (CTXR) announced it has received an extension from the Nasdaq Stock Market to regain compliance with the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market.
Key Details
- Compliance Deadline: Nasdaq has granted the company an extension until February 8, 2027, to satisfy the Bid Price Rule (Nasdaq Listing Rule 5550(a)(2)).
- Compliance Terms: To regain compliance, the company's common stock must have a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days before the deadline.
- Current Status: The extension notice has no immediate effect on the company's listing, and its stock will continue to trade on The Nasdaq Capital Market under the symbol "CTXR". If the company fails to regain compliance by the deadline, it will receive a delisting notice.